X0306 4 2020-09-28 1 0001510487 Principia Biopharma Inc. PRNB 0001752139 Becker Daniel J. C/O PRINCIPIA BIOPHARMA INC. 220 E. GRAND AVENUE SOUTH SAN FRANCISCO CA 94080 1 0 0 0 Common Stock 2020-09-28 4 U 0 667600 100.00 D 0 I See footnote Director Stock Option (right to buy) 17.00 2020-09-28 4 D 0 20475 D 2028-09-12 Common Stock 20475 0 D Director Stock Option (right to buy) 31.77 2020-09-28 4 D 0 10240 D 2029-06-10 Common Stock 10240 0 D Director Stock Option (right to buy) 62.66 2020-09-28 4 D 0 10240 D 2030-06-03 Common Stock 10240 0 D Pursuant to the Agreement and Plan of Merger, dated as of August 16, 2020, by and among Principia Biopharma Inc. (the "Issuer"), Sanofi ("Sanofi") and Kortex Acquisition Corp. ("Purchaser") (the "Merger Agreement"), on September 28, 2020, Purchaser merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Sanofi (the "Merger"). At the effective time of the Merger (the "Effective Time"), these shares were canceled in exchange for $100.00 per share in cash, without interest and subject to any applicable withholding taxes. The reported shares are held directly by AI Biotechnology LLC ("AIB"), a limited liability company of which the Reporting Person is the holder of units that are treated as profits interest units. The units owned by the Reporting Person do not convey a right to vote or dispose of the shares of the Issuer's Common Stock held by AIB. The Reporting Person disclaims beneficial ownership of all shares held by AIB and this report shall not be deemed an admission of beneficial ownership of such shares for the purposes of Section 16 or for any other purpose except to the extent of his pecuniary interest therein. Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options. /s/ Christopher Y. Chai, Attorney-in-Fact for Daniel J. Becker 2020-09-28